Broyles and EpimedX co-founder Robert Floyd are building the firm's first investment round. The funds will be used to complete preclinical tests and file the drug with the FDA. The next funding round will be for clinical trials.
Thanks to the perseverance of the EpimedX scientists and entrepreneurs, this Oklahoma firm is on a path to bring relief to Sickle Cell Disease sufferers around the world.
Rex Smitherman is interim president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state's technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Smitherman at i2E_Comments@i2E.org.
DID YOU KNOW?
If both parents have the sickle cell gene, there is a one in four chance of having a baby with Sickle Cell Disease. Eighty-five percent of the approximately 100,000 SCD sufferers in the U.S. are black, 10.6 percent are American Indian, and 4.4 percent are Hispanic-American, Asian-American, or Caucasian.